State and change from baseline after 3 months: all patients
| 3 months | 6 months | |||||||
|---|---|---|---|---|---|---|---|---|
| Overall | No co-medication | MTX co-medication | Overall | No co-medication | MTX co-medication | |||
| (n=328) | (n=123) | (n=205) | p Value | (n=284) | (n=98) | (n=186) | p Value | |
| Physician global* | 15.9 (15.0) | 18.5 (17.1) | 14.4 (13.5) | 0.02 | 14.9 (13.8) | 15.0 (13.5) | 14.8 (13.9) | 0.93 |
| Δ Physician global | −21.7 (22.1) | −20.0 (23.0) | −22.6 (21.7) | 0.32 | −23.1 (22.0) | −24.7 (21.4) | −22.2 (22.3) | 0.38 |
| Patient global* | 29.2 (23.9) | 32.4 (26.1) | 27.3 (22.3) | 0.07 | 28.8 (23.5) | 28.6 (22.3) | 29.0 (24.2) | 0.91 |
| Δ Patient global | −24.8 (26.4) | −22.0 (29.1) | −26.3 (24.7) | 0.17 | −24.8 (27.5) | −26.6 (28.6) | −23.9 (26.9) | 0.43 |
| MHAQ score (0–3) | 0.39 (0.41) | 0.42 (0.43) | 0.37 (0.40) | 0.30 | 0.38 (0.41) | 0.38 (0.41) | 0.38 (0.42) | 0.95 |
| Δ MHAQ score | −0.31 (0.44) | −0.30 (0.50) | −0.32 (0.39) | 0.67 | −0.30 (0.44) | −0.35 (0.50) | −0.27 (0.41) | 0.13 |
| SF-6D (0–1) | 0.70 (0.15) | 0.68 (0.15) | 0.70 (0.14) | 0.15 | 0.71 (0.14) | 0.68 (0.14) | 0.72 (0.15) | 0.10 |
| Δ SF-6D | 0.10 (0.13) | 0.10 (0.14) | 0.10 (0.13) | 0.92 | 0.11 (0.14) | 0.11 (0.14) | 0.11 (0.14) | 0.99 |
Mean (SD) values for continuous variables if not stated otherwise.
*(0–100).
MHAQ, Modified Health Assessment Questionnaire; MTX, methotrexate;SF-6D, Short Form 6 Dimensions.